The subgroup analysis by age group, sex, type and duration of TNF inhibitor and nbDMARD used, disease duration, and time to event in the matched cohort revealed that the adjusted HRs for cancer consistently tended to be lower in the TNF inhibitor cohort (Table S2). This evidence concerns the gene TNF and cancer.